HOME
LOGIN
THE MEDICAL LETTER
Subscribe
Current Issue
Previous Issues
Reference Tables
ABOUT US
The Medical Letter, Inc.
CONTINUING EDUCATION
Exams
DRUG INTERACTIONS
PRODUCTS
CONTACT US
The Medical Letter Mobile Home Page
CURRENT
ISSUE
1579
On August 6, 2019, the FDA issued a statement on data manipulation/inaccuracy issues with Zolgensma, a virus vector-based gene therapy approved for one-time IV treatment of children <2 years old with spinal muscular atrophy.1 We reviewed Zolgensma in our July 29 issue.2 According to the FDA statement, the manipulated data pertained to the production process for the product and did not affect the efficacy or safety results from the human clinical trials. It does not require any...  read more...
More from issue 1579
Advance Release
Coming Soon
Drugs for Atrial Fibrillation
Ezallor Sprinkle - A New Formulation of Rosuvastatin
Nasal Glucagon (Baqsimi) for Hypoglycemia
Influenza Vaccine for 2019-2020
Recommend to Your Library  

We're Essential.   Begin your free trial  
Previous Issues
© 2019 The Medical Letter, Inc.